Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Valbenazine (NBI-98854), a highly selective vesicular monoamine transporter 2(VMAT2) inhibitor, is approved for the treatment of tardive dyskinesia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 46.00 | |
2 mg | In stock | $ 67.00 | |
5 mg | In stock | $ 135.00 | |
10 mg | In stock | $ 197.00 | |
25 mg | In stock | $ 447.00 | |
50 mg | In stock | $ 647.00 | |
100 mg | In stock | $ 923.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 126.00 |
Description | Valbenazine (NBI-98854), a highly selective vesicular monoamine transporter 2(VMAT2) inhibitor, is approved for the treatment of tardive dyskinesia. |
In vivo | Valbenazine appeared to be well tolerated in adults with TD who received up to 48 weeks of treatment. In addition to long-term efficacy results, Suggest that valbenazine may be appropriate for the long-term management of TD regardless of underlying psychiatric diagnosis (SCHZ disorder or mood disorder)[1]. |
Animal Research | The pooled long-term exposure (LTE) population included valbenazine-treated subjects from 3 studies: KINECT; KINECT 3; KINECT4. Safety assessments included adverse events (AEs), laboratory tests, vital signs, electrocardiograms (ECGs), and extrapyramidal symptom (EPS) scales. Psychiatric stability was monitored using the Positive and Negative Syndrome Scale (PANSS) and Calgary Depression Scale for Schizophrenia (CDSS) (SCHZ subgroup), as well as the Montgomery-?sberg Depression Rating Scale (MADRS) and Young Mania Rating Scale (YMRS) (mood subgroup). All data were analyzed descriptively[1]. |
Synonyms | NBI-98854 |
Molecular Weight | 418.57 |
Formula | C24H38N2O4 |
CAS No. | 1025504-45-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (119.45 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Valbenazine 1025504-45-3 Membrane transporter/Ion channel Monoamine Transporter disease VMAT2 NBI 98854 monoamine transporter inhibit Huntington Inhibitor vesicular NBI-98854 NBI98854 inhibitor